Skip to main content
SpringerLink
Log in

Aftermath of myocardial infarction: ACE inhibitors prove their worth

  • Drug economics and quality of life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Le Pen C, Levy P. Le coût des maladies cardiovasularies. In: Grandjbakhch I, Ollivier JP, Pavie A, et al. La maladie coronaire: approches stratégiques et thérapeutiquies. Paris: Arnette Blackwell, 1995

    Google Scholar 

  2. Erhardt L, Ball S, Andersson F, et al. Cost effectiveness in the treatment of heart failure with ramipril. Pharmacoeconomics 1997; 12: 256–66

    Article  PubMed  CAS  Google Scholar 

  3. Michel BC, Al MJ, Remme WJ, et al. Economic aspects of treatment with Captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands. Eur Heart J 1996; 7: 731–40

    Article  Google Scholar 

  4. Erhardt L, Caidahl K, Eriksson H, et al. Hjärstvikt [Heart failure]. Stockholm: socialstyrelsen [The National Board of Health and Welfare], 1994 (SoS-report 1994: 3)

  5. McMurray J, Davie A. The pharmacoeconomics of ACE inhibitors in chronic heart failure. Pharmacoeconomics 1996; 9: 188–97

    Article  PubMed  CAS  Google Scholar 

  6. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669–77

    Article  PubMed  CAS  Google Scholar 

  7. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8

    Google Scholar 

  8. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–6

    Article  PubMed  CAS  Google Scholar 

  9. Megarry SG, Sapsford R, Hall AS, et al. Do ACE inhibitors provide protection for the heart in the clinical setting of acute myocardial infarction? Drugs 1997; 54 Suppl. 5; 48–58

    Article  PubMed  CAS  Google Scholar 

  10. Davie AP. ACE inhibitors after myocardial infarction: clinical and economic considerations. Pharmacoeconomics 2000 Mar; 7 (3): 237–43

    Article  Google Scholar 

  11. Le Pen C, Levy E, Bonte J. Cost-effectiveness analysis of Captopril treatment after myocardial infarction. Arch Mal Coeur Vaiss 1994; 87: 775–81

    PubMed  Google Scholar 

  12. Szucs T, Berger K, Schulte-Hillen J, et al. Cost effectiveness of Captopril after myocardial infarction. Med Klinik 1996; 91: 112–8

    CAS  Google Scholar 

  13. Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of Captopril therapy after myocardial infarction. J Am Coll Cardiol 1995; 26: 914–9

    Article  PubMed  CAS  Google Scholar 

  14. Hummel S, Piercy J, Wright R, et al. An economic analysis of the survival and ventricular enlargement (SAVE) study. Pharmacoeconomics 1997; 12: 182–92

    Article  PubMed  CAS  Google Scholar 

  15. LePen C, Lilliu H, Keller T, et al. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction. Pharmacoeconomics 1998; 14: 49–58

    Article  PubMed  CAS  Google Scholar 

  16. McMurray K, McGuire A, Davie AP, et al. Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction. Eur Heart J 1997; 18: 1411–5

    Article  PubMed  CAS  Google Scholar 

  17. Cleland JGF. ACE inhibitors for myocardial infarction: how should they be used? Eur Heart J 1995; 16: 153–9

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aftermath of myocardial infarction: ACE inhibitors prove their worth. Drugs Ther. Perspect 17, 13–15 (2001). https://doi.org/10.2165/00042310-200117100-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117100-00005

Keywords

Search

Navigation